onc Videos

Videos

Videos

Mitigating Potential Treatment Risks Among Patients With Myelofibrosis

02/02/2024

Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.

Aaron Gerds, MD, examines...

02/02/2024

Oncology

Videos

Exploring the Benefits of Momelotinib for Patients With Myelofibrosis, Including With Anemia

02/02/2024

Aaron Gerds , MD;

Aaron Gerds, MD, discusses the phase 3 MOMENTUM trial on momelotinib treatment for patients with myelofibrosis, including those with anemia, which served as the basis for the approval of momelotinib by the US FDA.

Aaron Gerds, MD, discusses the...

02/02/2024

Oncology

Conference Coverage

Real-World Response to Apalutamide vs Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

01/31/2024

Benjamin Lowentritt , MD;

Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.

Benjamin Lowentritt share...

01/31/2024

Oncology

Conference Coverage

Cabozantinib Plus Atezolizumab Showed Modest Activity Among Patients With Advanced Adrenocortical Carcinoma

01/31/2024

Enrique Grande , MD, PhD;

Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.

Enrique Grande, MD, shared...

01/31/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen , MD, PhD;

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia

01/29/2024

Asher Chanan-Khan , MD;

At the Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL).

At the Lymphoma, Leukemia &...

01/29/2024

Oncology

Conference Coverage

Utilizing BTK Inhibitors to Treat Patients With Chronic Lymphocytic Leukemia

01/29/2024

Javier Pinilla-Ibarz , MD, PhD;

During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.

During the Lymphoma, Leukemia &...

01/29/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Thomas Powles , MBBS, MD;

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Saby George , MD;

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Saby George shares insights from...

01/27/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden , MD;

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology